Fmr LLC Buys 188,368 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Fmr LLC lifted its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 2.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,019,746 shares of the company’s stock after purchasing an additional 188,368 shares during the quarter. Fmr LLC owned 5.57% of Denali Therapeutics worth $163,442,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Rhumbline Advisers grew its stake in Denali Therapeutics by 0.3% during the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock worth $3,880,000 after buying an additional 497 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after acquiring an additional 885 shares in the last quarter. E Fund Management Co. Ltd. grew its position in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after acquiring an additional 2,436 shares during the last quarter. KBC Group NV increased its holdings in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares in the last quarter. Finally, Swiss National Bank raised its position in Denali Therapeutics by 1.1% in the 4th quarter. Swiss National Bank now owns 253,500 shares of the company’s stock valued at $5,166,000 after purchasing an additional 2,800 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on DNLI shares. HC Wainwright increased their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Thursday. The Goldman Sachs Group reduced their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective for the company. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $37.57.

Denali Therapeutics Trading Up 1.6 %

Shares of DNLI opened at $12.70 on Friday. The stock has a market cap of $1.84 billion, a P/E ratio of -4.60 and a beta of 1.58. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $33.33. The stock’s 50-day moving average price is $16.53 and its two-hundred day moving average price is $21.83.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. As a group, equities analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.